Maa: Italia
Kieli: englanti
Lähde: HMA (Heads of Medicines Agencies)
derszy's disease virus 2.5 log10 CCID50, muscovy duck parvovirus inactivated 1.5 log10 SN.U
Merial
QI01BH01
Live freeze-dried pellet for suspension for injection
live goose parvovirus + inactivated duck parvovirus
Other Birds
2012-02-24
_ _ SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PARVOKAN 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.2-ml dose contains: ACTIVE SUBSTANCES: _Suspension_: Inactivated Muscovy duck parvovirus, GM strain, at least ...................................................... 1.5 log10 SN.U _Freeze-dried pellet_: Live attenuated Derzsy’s Disease virus, H strain, at least..................................................... 2.5 log10 CCID50 1 SN.U: q.s. to obtain a mean seroneutralizing antibody titre of 1 in the vaccinated animal ADJUVANT(S): _Suspension_: Al 3+ (as aluminium hydroxide) ............................................................................................................. 0.42 mg EXCIPIENT(S): _Suspension_: Thiomersal, at most ............................................................................................................................... 20 µg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Freeze-dried pellet and suspension for suspension for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Muscovy ducks. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES In Muscovy ducklings: Active immunisation against Muscovy duck parvovirosis and Derzsy’s Disease. The onset of immunity for both components was demonstrated from the age of 14 days, and lasts all the period of maximal susceptibility of ducklings (i.e. 4 weeks of age). 4.3 CONTRAINDICATIONS None known. 4.4 SPECIAL WARNINGS None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS - Vaccinate healthy animals only. - Apply the usual aseptic procedures. - Only Lue koko asiakirja